These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10218671)

  • 1. Expression of the proliferation and apoptosis-associated CAS protein in benign and malignant cutaneous melanocytic lesions.
    Böni R; Wellmann A; Man YG; Hofbauer G; Brinkmann U
    Am J Dermatopathol; 1999 Apr; 21(2):125-8. PubMed ID: 10218671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
    Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
    Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferative activity of primary cutaneous melanocytic tumours.
    Kuwata T; Kitagawa M; Kasuga T
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ.
    King R; Googe PB; Page RN; Mihm MC
    Mod Pathol; 2005 Aug; 18(8):1043-7. PubMed ID: 15803191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
    Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
    Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.
    Serban ED; Farnetani F; Pellacani G; Constantin MM
    Acta Dermatovenerol Croat; 2018 Apr; 26(1):64-67. PubMed ID: 29782304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intermediate filament peripherin is expressed in cutaneous melanocytic lesions.
    Prieto VG; McNutt NS; Lugo J; Reed JA
    J Cutan Pathol; 1997 Mar; 24(3):145-50. PubMed ID: 9085149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
    Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
    Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of staining for neurone specific enolase in benign and malignant melanocytic lesions of the skin.
    Dhillon AP; Rode J
    Diagn Histopathol; 1982; 5(3):169-74. PubMed ID: 6183082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
    Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
    Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
    Skender-Kalnenas TM; English DR; Heenan PJ
    J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topography of Protein Kinase C βII in Benign and Malignant Melanocytic Lesions.
    Krasagakis K; Tsentelierou E; Chlouverakis G; Stathopoulos EN
    Int J Surg Pathol; 2017 Sep; 25(6):497-501. PubMed ID: 28436290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
    Montone KT; van Belle P; Elenitsas R; Elder DE
    Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation.
    Skelton HG; Smith KJ; Barrett TL; Lupton GP; Graham JH
    Am J Dermatopathol; 1991 Dec; 13(6):543-50. PubMed ID: 1725245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
    Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
    J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.
    Sparrow LE; Eldon MJ; English DR; Heenan PJ
    Am J Dermatopathol; 1998 Jun; 20(3):255-61. PubMed ID: 9650698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
    Bayer-Garner IB; Hough AJ; Smoller BR
    Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
    Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
    Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.